| Biotechnology Industry | Healthcare Sector | Mr. Mingxu Yuan CEO | SSE Exchange | CNE100004397 ISIN |
| CN Country | 1,400 Employees | 2 Jun 2026 Last Dividend | 1 Jul 2024 Last Split | - IPO Date |
Chengdu Easton Biopharmaceuticals Co., Ltd. is a renowned entity in the pharmaceutical sector, founded in 2009 and headquartered in Chengdu, China. The company is deeply involved in the research, development, manufacture, and commercialization of pharmaceutical products. With a focus on innovation and quality, Chengdu Easton Biopharmaceuticals Co., Ltd. aims to contribute significantly to the health and well-being of people by providing effective medical solutions across various therapeutic fields. Their operations encompass a wide range of pharmaceutical formulations, catering to critical areas of healthcare including anesthetic/analgesics, cardiovascular, oncology, pediatrics, among others, thereby positioning the company as a key player in the pharmaceutical industry.
The company specializes in the production and distribution of finished dosage forms, catering to a variety of therapeutic fields. These include:
Chengdu Easton Biopharmaceuticals Co., Ltd. is also a prominent supplier of high-quality active pharmaceutical ingredients (APIs), which are pivotal in drug manufacturing. The categories include: